Real-World Outcomes with Lurbinectedin in Second Line and Beyond for Extensive Stage Small Cell Lung Cancer in Korea
Real-world data suggest that lurbinectedin is a viable option for patients with SCLC who have progressed on or after platinum-based chemotherapy.
Authors
- Min Hee Hong (ORCID: https://orcid.org/0000-0003-3490-2195)
- Jii Bum Lee (ORCID: https://orcid.org/0000-0001-5608-3157)
- Hye Ryun Kim (ORCID: https://orcid.org/0000-0002-1842-9070)
- Byoung Chul Cho (ORCID: https://orcid.org/0000-0002-5562-270X)
- Youhyun Kim
- Sun Min Lim (ORCID: https://orcid.org/0000-0001-5956-6920)
- J. Shim (ORCID: https://orcid.org/0000-0003-1461-9800)
- Taeho Yuh
Institutions
- Yonsei University (KR)
Publication Details
- Journal
- Lung Cancer Targets and Therapy
- Published
- 2024-10-01
- DOI
- https://doi.org/10.2147/lctt.s485320
- Citations
- 3
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.85
Funders
- American Society of Clinical Oncology
- PharmaMar